CRISPR Therapeutics AG
NASDAQ:CRSP
CRISPR Therapeutics AG
NASDAQ:CRSP
Price:
47.69
USD
-4.79%
Market Closed
Market Cap:
$4.6B
Balance Sheet
Balance Sheet Decomposition
CRISPR Therapeutics AG
CRISPR Therapeutics AG
Balance Sheet Decomposition is not available for
CRISPR Therapeutics AG
CRISPR Therapeutics AG
Balance Sheet
CRISPR Therapeutics AG
CRISPR Therapeutics AG
Currency: USD
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
1
|
156
|
316
|
240
|
457
|
944
|
1 169
|
923
|
212
|
389
|
298
|
348
|
|
| Cash |
1
|
156
|
316
|
240
|
457
|
944
|
1 169
|
923
|
212
|
389
|
298
|
348
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
522
|
1 456
|
1 603
|
1 304
|
1 606
|
1 628
|
|
| Total Receivables |
0
|
0
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
200
|
25
|
0
|
|
| Accounts Receivables |
0
|
0
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
200
|
25
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
2
|
6
|
10
|
44
|
26
|
38
|
38
|
14
|
8
|
10
|
|
| Total Current Assets |
1
|
157
|
320
|
248
|
466
|
988
|
1 717
|
2 418
|
1 853
|
1 908
|
1 937
|
1 986
|
|
| PP&E Net |
0
|
1
|
21
|
19
|
19
|
73
|
93
|
312
|
321
|
306
|
278
|
248
|
|
| PP&E Gross |
0
|
1
|
21
|
19
|
19
|
73
|
93
|
312
|
321
|
306
|
278
|
248
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
4
|
7
|
12
|
21
|
38
|
34
|
53
|
72
|
91
|
|
| Intangible Assets |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
53
|
2
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
1
|
3
|
4
|
4
|
6
|
18
|
22
|
16
|
14
|
27
|
32
|
|
| Total Assets |
2
N/A
|
159
+10 527%
|
345
+116%
|
271
-21%
|
489
+80%
|
1 067
+118%
|
1 828
+71%
|
2 752
+51%
|
2 243
-18%
|
2 230
-1%
|
2 242
+1%
|
2 265
+1%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
2
|
5
|
2
|
5
|
6
|
9
|
15
|
27
|
38
|
15
|
11
|
|
| Accrued Liabilities |
2
|
8
|
16
|
11
|
21
|
39
|
65
|
103
|
94
|
61
|
58
|
108
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
1
|
2
|
2
|
13
|
20
|
2
|
0
|
10
|
15
|
30
|
|
| Total Current Liabilities |
2
|
10
|
22
|
15
|
28
|
57
|
94
|
120
|
121
|
109
|
88
|
149
|
|
| Long-Term Debt |
0
|
38
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
76
|
90
|
69
|
69
|
70
|
70
|
233
|
247
|
238
|
222
|
194
|
|
| Total Liabilities |
2
N/A
|
124
+5 067%
|
112
-10%
|
84
-26%
|
97
+16%
|
127
+32%
|
164
+29%
|
352
+115%
|
368
+4%
|
347
-6%
|
310
-11%
|
343
+11%
|
|
| Equity | |||||||||||||
| Common Stock |
6
|
65
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
3
|
3
|
|
| Retained Earnings |
8
|
34
|
57
|
125
|
292
|
225
|
574
|
196
|
846
|
1 000
|
1 366
|
1 948
|
|
| Additional Paid In Capital |
1
|
5
|
289
|
312
|
682
|
1 162
|
2 236
|
2 598
|
2 735
|
2 878
|
3 294
|
3 862
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
16
|
2
|
2
|
5
|
|
| Total Equity |
1
N/A
|
35
N/A
|
233
+558%
|
188
-19%
|
392
+109%
|
939
+140%
|
1 664
+77%
|
2 400
+44%
|
1 876
-22%
|
1 883
+0%
|
1 932
+3%
|
1 922
-1%
|
|
| Total Liabilities & Equity |
2
N/A
|
159
+10 527%
|
345
+116%
|
271
-21%
|
489
+80%
|
1 067
+118%
|
1 828
+71%
|
2 752
+51%
|
2 243
-18%
|
2 230
-1%
|
2 242
+1%
|
2 265
+1%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
40
|
40
|
40
|
41
|
52
|
61
|
74
|
77
|
79
|
80
|
86
|
96
|
|
Switch to:
Switch to:
See Also
Discover More
